Flagship takes a deep dive into chromatin biology with Omega’s launch

How Flagship turns one investment in a therapeutic white space into a stronghold

With the launch of Omega, Flagship is strengthening its foothold in chromatin biology.

The VC launched Omega Therapeutics Inc. from its Flagship Labs incubator on Sept. 23 with undisclosed funding to selectively tune gene expression by targeting small loops of DNA in the 3-D chromatin structure

Read the full 463 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE